SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown? - 2South African radio presenter among five charged over Russia recruitment plot
- 3‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
- 4Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- 5This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- Artemis II astronauts are more than halfway to the moon as they seek to break Apollo 13's record
- What to watch for as NASA’s historic Artemis II crew prepares to lift off toward the moon
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Investigating the Advantages of a Bank account: A Complete Aide
- Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- Novartis eyes more bolt-on acquisitions, CEO says
- Vote in favor of Your Number one BWM Vehicles
- Protester climbs on to balcony of Iranian embassy in London
- Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
